{
    "clinical_study": {
        "@rank": "68812", 
        "arm_group": {
            "arm_group_label": "DA-8159", 
            "arm_group_type": "Experimental", 
            "description": "Udenafil(The study had one arm.)"
        }, 
        "brief_summary": {
            "textblock": "Phase : Phase III Indication : Erectile Dysfunction Study Design : open-label, fixed dose,\n      6-month extension study (parent study : DA8159_EDD_III)"
        }, 
        "brief_title": "Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Erectile Dysfunction", 
        "condition_browse": {
            "mesh_term": "Erectile Dysfunction"
        }, 
        "detailed_description": {
            "textblock": "Completer from parent study(DA8159_EDD_III)continued into a 24weeks open-label extension\n      during which they received udenafil once daily. The study concluded with a 4-week ED\n      treatment-free period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients aged 20 years or more diagnosed with erectile dysfunction(ED)\n\n        Exclusion Criteria:\n\n          -  Had uncontrolled blood pressure\n\n          -  Had hepatic or renal dysfunction\n\n          -  Had significant psychiatric disorders or drug abuses\n\n          -  Was currently under anticancer chemotherapy\n\n          -  Had a treatments for ED using other phosphodiesterase type 5(PDE-5) inhibitors"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "302", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901640", 
            "org_study_id": "DA8159_EDDL_III"
        }, 
        "intervention": {
            "arm_group_label": "DA-8159", 
            "intervention_name": "DA-8159 (Udenafil)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Udenafil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 15, 2013", 
        "number_of_arms": "1", 
        "official_title": "Phase 3 Study to Evaluate Longterm Safety of Once-a-Day Dosing of Udenafil in the Treatment of Erectile Dysfunction", 
        "overall_official": [
            {
                "affiliation": "the Catholic University of Korea St. Mary's Hospital", 
                "last_name": "S W Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Guro Hospital", 
                "last_name": "D G Moon, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "J J Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Pusan National University Hospital", 
                "last_name": "N C Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "S W Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "J S Paick, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "T Y Ahn, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yeungnam University", 
                "last_name": "K H Moon, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ewha Womans University Hospital", 
                "last_name": "W S Chung, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "K S Min, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonbuk National University Hospital", 
                "last_name": "J K Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kangdong Sacred Heart Hospital", 
                "last_name": "D Y Yang, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Safety evaluation included adverse events, standard 12-lead electrocardiograms and clinical laboratory measures. The AEs measured as percentage and number of patients.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks(after 24 weeks of parent study), 52weeks(after 28weeks of parent study)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901640"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The efficacy measures(Unit of Measure)\nIIEF EF domain score(Change from baseline)\nIIEF other domain scores(Change from baseline)\nGAQ & Shift to normal(percentage of subject)", 
            "measure": "International Index of Erectile Function(IIEF), GAQ(Global Assessment Questions), Shift to normal", 
            "safety_issue": "No", 
            "time_frame": "48 weeks(after 24 weeks of parent study), 52weeks(after 28weeks of parent study)"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}